CRINETICS PHARMACEUTICALS IN (CRNX) Stock Analyst Ratings
USA - NASDAQ:CRNX - US22663K1079 - Common Stock
41.41 USD
+1.33 (+3.32%)
ChartMill assigns a Buy % Consensus number of 83% to CRNX. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 81.09. This target is 95.82% above the current price.
CRNX was analyzed by 23 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about CRNX.
In the previous month the buy percentage consensus was at a similar level.
CRNX was analyzed by 23 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-09-30 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-09-29 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2025-09-29 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-09-26 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-09-26 | Baird | Maintains | Outperform -> Outperform |
| 2025-09-26 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2025-09-24 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-08-11 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-06-27 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-25 | Stifel | Initiate | Buy |
| 2025-02-28 | Citizens Capital Markets | Maintains | Market Outperform -> Market Outperform |
| 2025-02-04 | Wolfe Research | Initiate | Peer Perform |
| 2025-01-22 | Jefferies | Upgrade | Hold -> Buy |
| 2025-01-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-16 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-11-14 | Citigroup | Maintains | Buy -> Buy |
| 2024-11-13 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-09-27 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-09-16 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-08-09 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2024-08-09 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-07-09 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-07-02 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-06-28 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-04 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-06-04 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-06-04 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-23 | Baird | Maintains | Outperform -> Outperform |
| 2024-05-23 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2024-05-23 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
CRINETICS PHARMACEUTICALS IN / CRNX FAQ
What is the average price target for CRINETICS PHARMACEUTICALS IN (CRNX) stock?
23 analysts have analysed CRNX and the average price target is 81.09 USD. This implies a price increase of 95.82% is expected in the next year compared to the current price of 41.41.
What is the consensus rating for CRNX stock?
The consensus rating for CRINETICS PHARMACEUTICALS IN (CRNX) is 83.4783 / 100 . This indicates that analysts generally have a positive outlook on the stock.